Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 712 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Early cancer diagnosis and COVID-19: unpicking the impact of the pandemic December 20, 2022 Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab... July 9, 2021 Disguising Cancer as an Infection Helps the Immune System Eliminate Tumors July 22, 2022 Dad Creates Inclusive Children’s Book For Daughter With Disability And Others... January 25, 2022 Load more HOT NEWS Genetic discovery could guide treatment for aggressive childhood cancer The OncoLife Survivorship Care Plan: An Educational Tool For Survivors That... EMA Recommends Approval of the Marketing Authorisation for Tagraxofusp Mom Unknowingly Has Cancer For 3 Years After Doctor Keeps Telling...
